Controlled drug release for oral condition by a novel device based on ethylene vinyl acetate (EVA) copolymer.
The application of drug delivery systems in oral environment is relatively a new area of research with the exception of release of fluoride ions from polyalkenoate cements and their predecessor silicate cements. The present study addresses development of a novel device based on ethylene vinyl acetate copolymer (EVA), a biocompatible material which enables constant drug release over several days to treat oral infections. Drugs incorporated in EVA included tetracycline, minocycline and nystatin together with combinations (C) of nytatin-tetracycline (1 : 1) and nystatin-minocycline (1 : 1). Polymer casting solutions were prepared by dissolving EVA and the drugs in the ratio of 10 : 1 in 70 ml of dichloromethane at 38 degrees C for 6 h. Thin square films of 3x3 cm and 1 mm thickness were cut from the dry sheet obtained by solvent evaporation. Drug loaded samples were extracted for a minimum of 15 days in 10 ml medium (water or water/ethanol (1 : 2) or 0.9% saline solution) which is replaced daily. Spectral measurements were made to follow changes in optical densities (OD) during release kinetics. Analysis of the data revealed that among all the drugs tested tetracycline exhibited the highest release rate (56.15microg/cm2/day) and % cumulative release (27.92). The observed enhanced values may be interpreted as due to the channels formed due to changes in free volume (microvoids). In case of nystatin-minocycline combination, the observed increased values of release rates and percent cumulative release, may be attributed to the swelling component or channels or relative hydrophobic interactions. Initial "burst" effects due to liberation of surface-bound drug molecules were observed with reference to all the three drugs and the combinations of drugs studied. Among all the drugs, minocycline exhibited the least "burst" effect suggesting that the drug is more homogeneously distributed in the copolymer. Drug loaded EVA thermoplastic copolymer may provide a favorable therapeutic material for the development of a novel, local treatment for oral, mucosal and periodontal infections.